	2	with HIV	in the	Kingdom	of Eswatini
--	---	----------	--------	----------------	-------------

- Londiwe D. Hlophe^{1*}, Constance S. Shumba², Diribsa T. Bedada^{1,3}, Peter S. 4
- Nyasulu^{1,4*} 5

6

15

19

- **Affiliations** 7
- ¹ Division of Epidemiology and Biostatistics, Faculty of Medicine and Health Sciences, 8
- 9 Stellenbosch University, Cape Town, South Africa
- ² School of Nursing and Midwifery, Aga Khan University, Nairobi, Kenya 10
- 11 ³ Department of Public Health, College of Health Sciences, National Defence
- University, Addis Ababa, Ethiopia 12
- ⁴ Division of Epidemiology and Biostatistics, School of Public Health, Faculty of Health 13
- Sciences, University of the Witwatersrand, Johannesburg, South Africa 14
- *Corresponding authors 16
- Email: londiwehlope85@gmail.com (LDH) 17
- pnyasulu@sun.ac.za (PSN) 18

Abstract

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

Background: The success of antiretroviral therapy (ART) depends on a high level of adherence to the life-long therapy of 95% and above. However, in Eswatini, adolescents and young people aged 15 to 24 years, have poor ART adherence as evidenced by low viral load (VL) suppression rates (76% and 63% among female and males respectively) compared to the general population (96%). The wide age-band of 15 to 24 years in reporting viral suppression rates means that adolescent specific data is limited, and younger adolescents aged 10-14 years are excluded. This study explored the level of ART adherence and associated factors among adolescents living with HIV (ALHIV) aged 10 to 19 years on ART in Eswatini. Methods: We performed a retrospective analysis of 911 medical records of ALHIV aged 10 to 19 years on ART for at least a month in Eswatini for the period 1st January 2017 to 30th September 2022. Bivariate logistic regression was fitted for each predictor variable. Missing values were imputed using multiple imputation by chained equation (MICE). Statistically significant (p-value ≤0.2) predictor variables were included in a multivariable logistic regression model. P-value ≤0.05 was used to declare statistical significance in the final regression model. **Results:** ART adherence of 88.5% was recorded with higher adherence among males (88.9%) than females (87.8%). Hhohho region had highest adherence (90.7%) while Shiselweni region had lowest adherence (82%). Adherence was low among ALHIV with a non-suppressed baseline VL result (65.3%) and those assigned to multi-month ART model of care at ART initiation (66.7%). The Shiselweni region (OR 0.47; 95%CI 0.26-2.78), suppressed baseline VL result (OR 5.49; 95%CI 3.36-8,96) and assigned to the main-stream ART care model (OR 0.22; 95%Cl 0.05-0.95) were statistically

associated with ART adherence. In the multivariable regression analysis, only Shiselweni region and suppressed baseline VL result were statistically associated with ART adherence. Conclusion: Eswatini ALHIV have a low ART adherence compared to general population. Shiselweni region is negatively associated with ART adherence among ALHIV while a suppressed baseline VL is positively associated with improved ART adherence. There is therefore a need to intensify interventions aimed at early ART initiation and intensive follow-up and support among ALHIV especially in the Shiselweni region. **Keywords:** ART adherence; viral load suppression; adolescents living with HIV; Kingdom of Eswatini

1. Background

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

Globally, commendable strides have been made in attaining an optimum antiretroviral therapy (ART) adherence rate, and accordingly achieving viral load suppression (VLS) among people living with HIV (PLHIV). For instance, in the year 2021, 75% of PLHIV were on ART and 68% of these were virally suppressed [1,2]. In eastern and southern Africa which is home to 54% of all PLHIV globally, 79% of PLHIV were on ART, and of these, 78% were virally suppressed in 2021 [3.4]. ART adherence is defined as "the extent to which a personal behaviour in taking HIV medication, attending scheduled clinic appointments, following a diet or certain behaviour corresponds to the treatment and care plan conjointly agreed between the person living with HIV and the health worker" [5]. Optimum ART adherence, defined as 95% and above of correctly taking medication is a primary determinant of VLS [6]. Viral load suppression is viral load <1000 RNA copies per ml of blood and is critical in prevention of transmission of HIV to sero-negative partner, disease progression, opportunistic diseases, and AIDS-related deaths [5–7]. However, consistent with the evidence, globally, high ART uptake and VLS rates are only observed among the general population with adolescents reporting lower rates. yet adolescents account for 5% of all PLHIV [3,8]. The rates are even lower among ALHIV in sub-Sahara Africa (SSA) [1,3,9-11]. For instance, in 2021, VLS was only 30% among the 43% ALHIV on ART in SSA [12]. Furthermore, a systematic review including studies conducted between 2010 and 2022, reported an ART adherence rate of 65% and a VLS rate of 55% among ALHIV in SSA [13]. Similarly, studies conducted in South Africa, Kenya, Tanzania, and Uganda have reported even lower ART adherence rate ranging from 59% to 65% and VLS ranging from 22% to 73% [14–19].

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

Several factors associated with ART adherence have been identified among studies. These include age, sex, missing clinical appointment, presence of opportunistic diseases, duration on ART, ART regimen, family support, type of health facility, World Health Organization (WHO) clinical staging, VLS, and CD4-count [10,18,20-23]. The Kingdom of Eswatini formerly known as Swaziland has the highest Human Immuno-deficiency Virus (HIV) prevalence of 27% globally with an incidence of 1.4 among those 15 years and above [24]. Females are mostly affected in the country with an HIV prevalence of 32.5% compared to 20.4% among males [25]. Secondly, the HIV prevalence is disproportionally high at 7.3% among female adolescents aged 15 to 19 years compared to their male counterparts at 3.9% [25]. HIV prevention and management is critical among adolescents not only in Eswatini, but in the sub-Saharan Africa (SSA) region which is home to 90% of adolescents living with HIV (ALHIV) [3]. Eswatini is among the first countries globally to meet the 95-95-95 (95% people living with HIV knowing their HIV status, 95% of these on ART and 95% of those on ART viral load suppressed) UNAIDS global targets in the general population ahead of the year 2030 [26]. Viral load suppression (VLS) was reported to be 96% as of 2022 in the country, from 91% in 2017 [25,26]. This has been attributed to the uninterrupted access and availability of antiretroviral therapy (ART) among those testing positive to HIV and programmes aimed at supporting ART adherence [27]. However, these positive gains are only observed among the general population while ALHIV still present poor HIV treatment outcomes [28]. For instance, in 2017 Eswatini reported 89% of the people living with HIV (PLHIV) on ART with 91% of them virally suppressed. However, among ALHIV and young people, only 81.7% were on ART and

76.4% virally suppressed [25]. The discrepancies in viral load suppression rate among

perpetuity.

It is made available under a CC-BY 4.0 International license.

adolescents and general population, are an indication of poor HIV prevention and management, particularly poor ART adherence among ALHIV.

Unfortunately, there is limited HIV data on adolescents aged 10 to 19 years in Eswatini due to the wide description age-band of 15 to 24 years. Therefore, this study aimed to assess the level of ART adherence and associated factors among ALHIV aged 10 to 19 years on ART in Eswatini.

2. Methods

2.1 Study design and population

This was a retrospective study design which used data from the Eswatini Ministry of Health, Health Management Information System [HMIS]. Data extraction was done using a chart abstraction tool from the Client Management Information System (CMIS) for adolescents who accessed care and tested HIV positive between the periods of January 2017 and 30 September 2022. In 2017, Eswatini adopted and implemented the universal test and treat guidelines and the same year, the CMIS was rolled out in all the health facilities in the country [29]. The CMIS is a national electronic medical record system aimed at tracking and caring for patients visiting health facilities in the country. The system consolidates all the medical history of patients into one data set allowing for comprehensive health information of patients [29].

2.2 Inclusion and exclusion criteria

This study included ALHIV who were enrolled and initiated in ART at age 10–19 with either vertical or horizontal HIV infection from 1st January 2017 to 30th September 2022. Only ALHIV and had been on ART for at least a month were included in this study. ALHIV who transitioned from paediatric care were excluded from this study. Secondly, ALHIV whose records had missing details of latest or current viral load (VL) result in the CMIS database were excluded from the study. Current or latest VL result

2.3 Ethical approval

was defined as the last available VL result.

Approval to carry out the study was sought from the Eswatini Health and Human Research Review Board of the Ministry of Health and a waiver of consent was obtained from the Board (Protocol Reference Number: EHHRRB103/2022). A waiver not to acquire participants' informed consent was granted by the same board as this study involved secondary data analysis. Anonymity was maintained by de-identifying the data and assigning codes instead of names during the chart abstraction process.

2.4 Study setting

The data involved ALHIV enrolled in ART care from 1st January 2017 to 30th September 2022 in the Kingdom of Eswatini and registered in CMIS database. In 2015, adolescents accounted for 10% of all those in HIV treatment in the country [30]. Adolescents access care through a differential ART service delivery model which includes expert client offered by lay heath workers (LHWs) through Teen Clubs, multi-

months (3 and 6 months) refills, as well as the mainstream model [31,32]. The expert client approach involves training LHWs on HIV treatment adherence, stigma and disclosure, and HIV linkage to care and communication and counselling skills [33,34]. The mainstream model also known as the standard of care model provides direct patient monitoring by a nurse or a doctor mostly for patients newly initiated to ART, with detectable VL, with ART adherence issues, or suspected treatment failure [35]. In 2021, there were 10,153 ALHIV in the country while there were 81 Teen Clubs with 3,742 adolescents aged 10 to 19 years as members. The country has 327 health facilities; one (1) national referral hospital, three (3) specialized hospitals, five (5) regional referral hospitals, five (5) health centres, six (6) public health units, 297 clinics of which 65 are specialized clinics, and nine (9) private hospitals [36]. These health facilities are distributed in the four regions (Hhohho, Manzini, Lubombo and Shiselweni) of the country with the national referral hospital in the Hhohho region.

Study sample 2.5

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

A total 3.420 ALHIV aged 10 to 19 were enrolled on ART care between 1st January 2017 and 30th September 2022. Of these, 911 were included in the analysis as they met the inclusion criteria. Among the 911, some had missing data in one or more variables. We imputed the missing information using Multivariate Imputation by Chained Equations (MICE) for the variables we decided to include into the final multivariable regression model.

2.6 Measurements

All participants were followed for the period between January 2017 up until September 2022. Only ALHIV enrolled on ART between 1st January 2017 and September 2022 were included in this study. Our primary outcome was ART adherence defined as 95% of correctly taking ART which was estimated using the viral load suppression rate where viral load suppression was defined as viral load <1000 RNA copies per ml of blood, a standard VLS measurement used in Eswatini [37].

Predictor variables included: demographic and social factors (sex, age, region), HIV factors (age at diagnosis, baseline VL result, latest viral load result, ART start date, time on ART, model of ART care at initiation, latest or current model of ART care, regimen, CD4 count result, and WHO clinical staging), and facility factors (facility ownership). Baseline VL result was defined as the first VL result after a positive HIV diagnosis. Facility ownership included government, non-government, private and mission.

Statistical analysis 2.7

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

The dataset in Excel was exported to Stata for the data analysis, and the analysis was done using the Stata statistical software, release 16, College Station, TX, Stata Corp LLC. Data analyses were conducted at descriptive, bivariate, and multivariable levels. Continuous variables (age, years at HIV diagnosis and years on ART) were presented as means with standard deviations and categorical variables were presented as frequencies and percentages. Differences in characteristics between ALHIV who were adherent versus those who were non-adherent were assessed using the chi-square

test. Associations between ART adherent and independent variables were examined using the Pearson' chi-square test. Variables that were significantly associated with ART adherence at bivariate analysis at significance level of ≤ 0.2 were selected and included in the multivariable regression model. Age and sex were included despite their lack statistical significance. Due to high missing data in some of the variables, a Multiple Imputation by Chained Equation (MICE) was conducted to impute the missing values. Backward elimination was used in building the final model whereby variables which did not contribute at p-value <0.05 were eliminated and a new model fitted. All variables that were significant at p<0.05 were kept in the final multivariable logistic regression model.

3. Results

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

Socio-demographic characteristics of participants 3.1

A total of 3420 medical records were reviewed of which only 911 were included in the analysis. Six-hundred-and-six (66.6%) adolescents were in the age group 15 to 19 years and 155 (60%) were females. The mean age of the ALHIV and on ART was 16.3 (SD 3.3). Majority (355; 39%) of the adolescents were from the Hhohho region while only 133 (15%) were from the Shiselweni region (Table 1).

Clinical and Treatment-Related Characteristics 3.2

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

The average age at diagnosis of adolescents was 14 years (SD 4.2). Most adolescents (355; 70%) were enrolled under government owned health facilities while only 123 (13.5%) were enrolled in both private and non-government health facilities. Government health facilities include both military and non-military health facilities. Among adolescents with a recorded CD4 count results, 158 (60%) were on either World Health Organization (WHO) clinical stage three or stage 4 as a baseline CD4 count result. As of 2022 (latest CD4 result), only 81 out of 141 adolescents with CD4 count result were on either of these stages. Seven-hundred-and-fifty-eight (83%) of the adolescents had been on ART for 2 years and above. At baseline, 714 (88%) adolescents were virally load suppressed (Table 1). Overall, ART adherence was 88.5% among adolescents. The age group 15 to 19 years had higher adherence (89.3%) compared to 10-14 years (86.9%). Hhohho region recorded 90.7% ART adherence followed by Manzini (89.5%), Lubombo (87.50%), while Shiselweni had the lowest adherence rate of 81.95% (Table 1).

Table 1: Characteristics of study participants stratified by ART adherence

Variable	Total N=911a	Adherence (n, %)	Non-adherent (n, %)	p-value
Age group				
10-14	305	265 (86.89%)	40 (13.11%)	
15-19	606	541 (89.27%)	65 (10.73%)	0.287
Sex				
Female	551	490 (88.93%)	61 (11.07%)	
Male	360	316 (87.78%)	44 (12.22)	0.595
Region				
Hhohho	355	322 (90.70%)	33 (9.30%)	
Lubombo	184	161 (87.50%)	23 (12.5%)	
Manzini	239	214 (89.54%)	25 (10.46%)	0.052

Shiselweni	133	109 (81.95%)	24 (18.05%)	
Facility Ownership				
Government	641	567 (88.46%)	74 (11.54%)	
			,	0.945
NGO	123	108 (87.8%)	15 (12.2%)	
Faith-based	147	131 (89.12%)	16 (10.88%)	
ART Duration				
<2 years	153	139 (90.85%)	14 (9.15%)	
≥2years	758	667 (87.99%)	91 (12.01%)	0.313
ART Regimen				
1 st Line	430	387 (90%)	43 (10%)	
2 nd Line	17	13 (76.5%)	4 (23.5%)	0.074
Baseline WHO Stage				
I-II	104	91 (87.5%)	13 (12.5%)	
III-IV	158	142 (89.87%)	16 (10.13%)	0.549
Latest WHO Stage				
I-II	60	48 (80%)	12 (20.0%)	
III-IV	81	72 (88.89%)	9 (11.11%)	0.143
Baseline VLS				
No	98	64 (65.31%)	34 (34.69%)	
Yes	714	651 (91.18%)	63 (8.82%)	0.0000*
ART Model of Care at	Initiation			
Multi-Months	3	2 (66.67%)	1 (33.33%)	
Mainstream	416	371 (89.18%)	45 (10.87%)	0.393
Teen Clubs	37	34 (91.89%)	3 (8.11%)	
Current Model of AR	Γ Care			
Multi-Months	66	64 (96.97%)	2 (3.03%)	
Mainstream	433	379 (87.53%)	54 (12.47%)	
Teen Clubs	338	302 (89.35%)	36 (10.65%)	0.058
Fast Track	17	17 (100%)	0	

^{*}Statistically significant

Factors Associated with ART Adherence among 3.3

ALHIV 244

240

241

242

^a some sample sizes for variables may not add up to N due to missing data

246

247

248

249

250

251

252

253

254

255

256

In the bivariate logistic regression analysis, Shiselweni region, viral load suppressed at initiation and mainstream at current ART care model were statistically significant predictors and were fitted in the multivariable logistic regression model (Table 2). In the multivariable regression model (Table 3), only Shiselweni and baseline or initial viral load suppressed were predictors of ART adherence.

The odds of adolescents from Shiselweni region were negatively associated (OR=0.54, 95%CI: 0.17-0.96) with ART adherence than adolescents from the other region of the country. The odds of adolescents with a suppressed baseline viral load were (OR=6.22, 95% CI: 4.13-10.56) almost six-fold likely to adhere to ART compared to those who were non-virally load suppressed (Table 3).

Table 2: Factors associated with ART adherence among ALHIV

Variable	OR	p-value	95% CI
Age	I	I	
10-14	Ref		
15-19	1.26	0.287	0.83-1.91
Sex			
Female	Ref		
Male	0.89	0.595	0.59-1.35
Region			
Hhohho	Ref		
Lubombo	0.72	0.249	0.41-1.26
Manzini	0.88	0.639	0.51-1.52
Shiselweni	0.47	0.008*	0.26-2.78
Facility Ownership	1	1	

Government	Ref		
Non-government and Private	0.92	0.789	0.51-1.67
Faith-based	1.07	0.820	0.60-1.89
ART Duration	<u> </u>		
<2 years	Ref		
≥2 years	0.74	0.315	0.41-1.33
Regimen			
1 st Line	Ref		
2 nd Line	0.36	0.086	0.11-1.16
Baseline VLS		,	
No	Ref		
Yes	5.49	0.000*	3.36-8.96
Baseline WHO stag	je	,	
I-II	Ref		
III-IV	1.27	0.550	0.58-2.78
Latest WHO stage		,	
1-11	Ref		
III-IV	2	0.148	0.78-5.11
ART Model of Care	at Initiation	,	
Multi-Month	Ref		
Mainstream	4.12	0.251	0.37-46.37
Teen Club	5.67	0.204	0.39-82.24
Current ART Model	of Care	1	
Multi-Month	Ref		
Mainstream	0.22	0.038*	0.05-0.92
Teen Club	0.26	0.070	0.06-1.12

^{*}Statistically significant

Table 3: Multivariate Logistic Regression showing factors associated with ART

adherence among ALHIV

258

259

260

Variable	OR	p-value	95% CI
Age group			
10-14	Ref		
15-19	1.49	0.231	0.81-2.54
Sex			
Female	Ref		
Male	1.35	0.632	0.72-1.98
Region		I	
Hhohho	Ref		
Lubombo	0.86	0.412	0.52-1.73
Manzini	0.90	0.512	0.63-1.79
Shiselweni	0.54	0.029*	0.17-0.96
Baseline VLS			
No	Ref		
Yes	6.22	0.001*	4.13-10.56
Current ART Mo	odel of Care		
Multi-Month	Ref		
Mainstream	1.23	0.661	0.67-2.23
Teen Clubs	0.94	0.623	0.58-2.14
Constant	8.22	0.031	2.65-24.812

^{*}Statistically significant

4. Discussion

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

The study revealed the determinants of ART adherence among ALHIV in the Kingdom of Eswatini. In this study, the mean age was 16.3 (SD 3.3) years with more females (551, 60%) compared to males (360, 40%). On average, adolescents were initiated on ART at the age of 14 years (SD 4.2). The study discovered that overall, ART adherence among ALHIV was sub-optimal at 88.5% which is lower than the 95% ART adherence rate required for suppressed viral load. When compared to other studies, ART adherence among Swati adolescents was higher than in studies conducted among ALHIV in South Africa (65%), Kenya (76%) and Zimbabwe (28%) while comparable with studies conducted in Nigeria (85%), Uganda (80%), Cameroon (83%) [10.16.22.38-40]. These discrepancies among the countries could be due to the differences in outcome measurements, settings, sample sizes, and study designs as explained in a study conducted in Ethiopia among children on ART [21]. Nevertheless, an ART adherence rate below 95% is associated with unsuppressed viral load which is further associated with opportunistic infections, drug resistance and subsequently death [7]. For instance, in two studies conducted in South Africa, lower ART adherence rate was statistically associated with increased opportunistic infections and a two-fold (OR 1.98) likelihood of a detectable viral load [41,42]. Another study conducted among ALHIV in South Africa reported that poor ART adherence was also associated with virologic failure [43]. A study conducted in Liberia also revealed that poor ART adherence was associated with loss to follow up and experiences of drug side effects [44]. Secondly, the study findings indicate that Shiselweni region is a predictor of poor ART adherence compared to the other regions. This finding is not comparable to the

national findings which indicate that generally the Shiselweni region has the highest

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

HIV prevalence (26.5%) compared to the other regions but not statistically associated with either viral load suppression or ART adherence [27]. The Swaziland HIV Incidence measurement survey (SHIMS II) also reported that the different HIV prevalence rates in the four regions of the country had no significant difference [25]. However, findings of this study have revealed that there is an association between ART adherence and region among ALHIV. This could be because previous studies were conducted among the general population or adult population while this study was conducted among adolescent age group. Studies conducted in the Shiselweni region revealed that the universal test and treat (UTT) HIV program has been associated with low retention to care partly due to status non-acceptance by those tested positive and other factors such as transport costs and distance to health facilities [45-47]. The Shiselweni region is ranked the poorest region in the country with high food and water insecurities [46,48]. According to the Eswatini operational plan of 2020, the population of the Shiselweni region is hard-to-reach with limited access to health services and HIV prevention, control, and management services such as HIV testing and VL testing since it is dynamic and very evanescent because of the recent influx and growth of textile factories, and it harbours the main truck route and border gate [48]. The region is therefore a hot spot for at-risk population [48]. The delayed initiation of ART due to low testing in the Shiselweni region has been associated with poor ART outcomes such as low viral load suppression among those who are eventually tested in the region [46,47].

According to studies conducted in Uganda and South Africa, retention to care was a positive predictor of ART adherence while a study conducted in South Africa also revealed that distance to health facilitator was statistically associated with ART

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

adherence [18,49]. Studies aimed at improving the financial capacity of ALHIV have reported a positive association with retention to care and ART adherence [50–54]. This has been facilitated by financial incentives aimed at assisting ALHIV with money for honouring their hospital appointments, curbing food insecurities among others. For instance, a study conducted in Uganda which was aimed at evaluating the efficacy of economic incentive in improving ART outcomes such as viral load suppression and adherence among ALHIV, presented a ten-fold increase among those receiving the economic incentive compared to standard of care [52]. However, status acceptability has been reported to be associated with retention to care and ART adherence. In studies conducted in Zambia, Tanzania and South Africa, early status disclosure among adolescents was associated with early acceptability of status and thus treatment adherence [55–57]. Additionally, a study conducted by Cluver et al. (2015) revealed that adolescents who had their status disclosed early were three times likely to be retained in care and thus improved ART adherence [55]. However, other studies have reported that adolescents whose status were revealed early were most likely to miss medication doses due to treatment fatigue [49,58]. These contradicting findings are justified by Ankrah et al. (2016) because of lack of support system among ALHIV especially older adolescents as care-giver responsibility reduces and adolescents are at a self-discovery stage [59]. Nevertheless, early treatment to initiation and adherence to the treatment are critical in improving ART outcomes. WHO guidelines have established a positive association between early treatment initiation and improved ART outcomes such as viral load suppression which are associated with optimum ART adherence among those on ART [6]. Early initiation to ART is facilitated by the availability of health services promoting HIV testing for early diagnosis and subsequent treatment through the UTT approach [6,18].

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

Lastly, the study revealed that baseline viral load suppression is a positive predictor for ART adherence as revealed in other studies. Numerous studies have reported the association between VLS and ART adherence. High viral load suppression is positively associated with optimum ART adherence while non-viral load suppression is a predictor for poor ART adherence [60–67]. For instance, in a study conducted in Kenya, adolescents and children with a suppressed viral load were mostly likely to adhere to treatment compared to those with a high viral load at ART initiation [68]. Furthermore, the UTT has been based on scientifically proven evidence that early initiation to ART is effective in ensuring positive ART outcome such as reduced AIDS related morbidity and mortality [69–73]. The positive ART outcomes are enabled by the low viral load which associated with ART adherence. The strength of our study is that the results demonstrate the current ART adherence level and key associated factors (demographic and social factors, HIV factors, and facility factors) among ALHIV aged 10 to 19 years, a population group normally reported with young adults and paediatrics. Secondly, since the study used the national dataset, the study results can extrapolate the current ART adherence situation in Eswatini specifically among ALHIV. Additionally, since secondary data was used. recall and reporting bias were eliminated. Also, the data collection process was informed by professionalism and expertise, and not associated with research thus was not subject to interview bias. Lastly, being the only study conducted among adolescents within this age group, our study can contribute to informing policies, plans, and service delivery strategies for preventing and controlling poor ART adherence among ALHIV in Eswatini. Nonetheless, some limitations should be considered when interpreting the findings of this study. Firstly, this was a retrospective study that used secondary data for analysis that was not intentionally collected for this study, and therefore limited the study in evaluating other predictors of ART adherence which were not covered in the records. Secondly, being a secondary dataset made the data prone to missing variables due to incomplete documentation. However, we are confident that the available data provide true estimation as it was captured by qualified health professionals.

5. Conclusions

In conclusion, our results demonstrate that ART adherence is sub-optimum among ALHIV in Eswatini despite the positive progress in attaining the 95-95-95 UNAIDS 2030 target by the general population. It is critical to better understand why adolescents have a sub-optimum adherence rate and device strategies aimed at improving ART adherence among ALHIV in Eswatini. These results highlight an urgent need to innovate strategies aimed at improving early ART initiation and intensive follow-up and support among ALHIV especially in the Shiselweni region.

6. List of abbreviations

AIDS, Acquired Immune Deficiency Syndrome; OR, Odds ratio; ART, Anti-Retroviral Therapy; HIV, Human Immunodeficiency Virus; VL, Viral Load; VLS, Viral Load suppression; ALHIV, Adolescents Living with HIV; PLHIV, People Living with HIV; WHO, World Health Organization; CMIS, Client Management Information System; SSA, sub-Sahara Africa; LHW, Lay Health Worker; UTT, Universal Test and Treat

7. Declaration

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

Ethics approval and consent to participate: Ethical approval for conducting the study was sought from the Eswatini Health and Human Research Review Board of the Ministry of Health and a waiver of consent was obtained from the Board since the study used secondary data (Protocol Reference Number: EHHRRB103/2022). Consent of publication: The Eswatini Health and Human Research Review Board of the Ministry of Health granted the consent for publication of the findings of the study. Availability of data and materials: Data underlying the findings of the study are included in the paper. **Competing interests:** The authors report that there was no conflict of interest in this work. **Funding:** The authors received no specific funding for this work. **Authors' contribution:** Conceptualization: Londiwe D. Hlophe, Peter S. Nyasulu, Constance S. Shumba Dara curation: Londiwe D. Hlophe, Diribsa T. Bedada Formal analysis: Londiwe D. Hlophe, Diribsa T. Bedada Investigation: Londiwe D. Hlophe Methodology: Londiwe D. Hlophe, Diribsa T. Bedada, Constance S. Shumba, Peter S. Nyasulu Writing-original draft preparation: Londiwe D. Hlophe

Writing- review and editing: Londiwe D. Hlophe, Diribsa T. Bedada, Constance S. 405

Shumba, Peter S. Nyasulu

406

407

408

409

410

411

412

413

Acknowledgement: The authors would like to thank the management and staff from

the Ministry of Health; Health Management Information System for the support

provided during the duration of the study. Special gratitude is also forwarded to Dr.

Garikai Chemhaka for his valuable support throughout the study.

References

- UNAIDS. Global HIV & AIDS statistics Fact sheet | UNAIDS [Internet]. 2022 1. 414
- [cited 2021 Aug 24]. Available from: https://www.unaids.org/en/resources/fact-415
- sheet 416
- 2. UNICEF. HIV Statistics - Global and Regional Trends - UNICEF DATA 417
- [Internet]. 2021 [cited 2021 Aug 24]. Available from: 418
- 419 https://data.unicef.org/topic/hivaids/global-regional-trends/
- UNICEF. HIV and AIDS in Adolescents UNICEF Data [Internet]. 2021 [cited 3. 420
- 2021 Jan 12]. Available from: https://data.unicef.org/topic/adolescents/hiv-aids/ 421
- 4. UNAIDS. UNAIDS 2021 epidemiological estimates. 2021 [cited 2021 Aug 24]. 422
- Global HIV & AIDS statistics Fact sheet | UNAIDS. Available from: 423
- https://www.unaids.org/en/resources/fact-sheet 424

5. WHO. Global HIV Programme [Internet]. 2022 [cited 2022 Oct 7]. Available 425 from: https://www.who.int/teams/global-hiv-hepatitis-and-stis-426 programmes/hiv/treatment/service-delivery-adherence-retention 427 6. WHO. WHO publishes new Consolidated HIV guidelines for prevention, 428 treatment, service delivery & monitoring [Internet]. 2021 [cited 2022 Aug 10]. 429 Available from: https://www.who.int/news/item/16-07-2021-who-publishes-new-430 consolidated-hiv-guidelines-for-prevention-treatment-service-delivery-431 monitoring 432 7. Hine P, Smith R, Eshun-Wilson I, Orrell C, Cohen K, Leeflang MMG, et al. 433 Measures of antiretroviral adherence for detecting viral non-suppression in 434 people living with HIV. Cochrane Database of Systematic Reviews. 435 2018;2018(7). 436 UNAIDS. Global HIV & AIDS statistics — Fact sheet | UNAIDS [Internet]. 2021 8. 437 [cited 2021 Oct 15]. Available from: https://www.unaids.org/en/resources/fact-438 sheet 439 9. Adejumo OA, Malee KM, Ryscavage P, Hunter SJ, Taiwo BO. Contemporary 440 issues on the epidemiology and antiretroviral adherence of HIV-infected 441 adolescents in sub-Saharan Africa: A narrative review. J Int AIDS Soc 442 [Internet]. 2015;18(1):20049. Available from: 443 http://dx.doi.org/10.7448/IAS.18.1.20049 444 N Tanyi W, Gachuno O, Odero T, Farguhar C, Kimosop D, Mayi A. Factors 10. 445 affecting adherence to antiretroviral therapy among children and adolescents 446

living with HIV in the Mbita Sub County Hospital, Homa Bay- Kenya. Afr Health 447 Sci. 2021 May 23;21(1):18-24. 448 Amour MA, Shayo GA, Matee MM, Machumi L, Rugarabamu A, Aris EA, et al. 11. 449 Predictors of mortality among adolescents and young adults living with HIV on 450 antiretroviral therapy in Dar es Salaam, Tanzania: a retrospective cohort study. 451 J Int AIDS Soc [Internet]. 2022 Feb 1 [cited 2022 Aug 3];25(2):25886. 452 Available from: /pmc/articles/PMC8863353/ 453 12. Vreeman RC, Rakhmanina NY, Nyandiko WM, Puthanakit T, Kantor R. Are we 454 there yet? 40 years of successes and challenges for children and adolescents 455 living with HIV. J Int AIDS Soc [Internet]. 2021 Jun 1 [cited 2022 Jul 18];24(6): 456 e25759. Available from: 457 https://onlinelibrary.wiley.com/doi/full/10.1002/jia2.25759 458 Hlophe LD, Jacques L. Tamuzi, Constance S. Shumba PSN. Barriers and 13. 459 facilitators to anti-retroviral therapy adherence among adolescents aged 10 to 460 19 years living with HIV in sub-Saharan Africa: A mixed-methods systematic 461 review and meta-analysis. PLoS One [Internet]. 2023 Mar 18;18(5): e0276411. 462 463 Available from: http://dx.doi.org/10.1371/journal.pone.0276411 Bitwale NZ, Mnzava DP, Kimaro FD, Jacob T, Mpondo BCTT, Jumanne S. 14. 464 Prevalence and Factors Associated with Virological Treatment Failure among 465 Children and Adolescents on Antiretroviral Therapy Attending HIV/AIDS Care 466 467 and Treatment Clinics in Dodoma Municipality, Central Tanzania. J Pediatric Infect Dis Soc. 2021 Mar;10(2):131-40. 468

15. Brathwaite R, Ssewamala FM, Neilands TB, Okumu M, Mutumba M, Damulira 469 C, et al. Predicting the individualized risk of poor adherence to ART medication 470 among adolescents living with HIV in Uganda: the Suubi+Adherence study. J 471 Int AIDS Soc. 2021 Jun;24(6): e25756. 472 Haghighat R, Toska E, Bungane N, Cluver L. The HIV care cascade for 473 16. adolescents initiated on antiretroviral therapy in a health district of South 474 Africa: a retrospective cohort study. BMC Infect Dis [Internet]. 2021 Jan [cited 475 2021 Aug 20];21(1):60. Available from: https://doi.org/10.1186/s12879-020-476 05742-9 477 Zhou S, Cluver L, Shenderovich Y, Toska E. Uncovering ART adherence 17. 478 inconsistencies: An assessment of sustained adherence among adolescents in 479 South Africa. J Int AIDS Soc [Internet]. 2021 Oct;24(10): e25832. Available 480 from: 481 http://onlinelibrary.wiley.com/doi/10.1002/jia2.25832/full%7Chttps://doi.org/10. 482 483 1002/jia2.25832 Cluver L, Pantelic M, Toska E, Orkin M, Casale M, Bungane N, et al. 18. 484 485 STACKing the odds for adolescent survival: health service factors associated with full retention in care and adherence amongst adolescents living with HIV 486 in South Africa. J Int AIDS Soc. 2018 Sep;21(9): e25176. 487 19. Chory A, Callen G, Nyandiko W, Njoroge T, Ashimosi C, Aluoch J, et al. A Pilot 488 489 Study of a Mobile Intervention to Support Mental Health and Adherence Among Adolescents Living with HIV in Western Kenya. AIDS Behav [Internet]. 490 2022 Jul 22 [cited 2021 Nov 24];26(1):232–42. Available from: 491

https://doi.org/10.1007/s10461-021-03376-9

- 20. Watt MH, Maman S, Golin CE, Earp JA, Eng E, Bangdiwala SI, et al. Factors 493 associated with self-reported adherence to antiretroviral therapy in a 494 Tanzanian setting. AIDS Care. 2010 Mar;22(3):381–9. 495 21. GebreEyesus F, Mitku D, Tarekegn T, Temere B, Terefe T, Belete A, et al. 496 Levels of Adherence and Associated Factors Among Children on ART Over 497 Time in Northwest, Ethiopia: Evidence from a Multicenter Follow-Up Study. 498 HIV AIDS (Auckl). 2021; 13:829-38. 499 Bongfen MC, Torpey K, Ganle J, Ankomah A. Level of adherence and 500 22. associated factors among HIV-positive adolescents on antiretroviral therapy in 501 Cameroon. Afr J AIDS Res. 2020 Dec;19(4):269-75. 502 Kim MH, Mazenga AC, Yu X, Ahmed S, Paul ME, Kazembe PN, et al. High 23. 503 self-reported non-adherence to antiretroviral therapy amongst adolescents 504 living with HIV in Malawi: Barriers and associated factors. J Int AIDS Soc. 505 2017;20(1):1–12. 506 Justman J, Reed JB, Bicego G, Donnell D, Li K, Bock N, et al. Swaziland HIV 507 24. Incidence Measurement Survey (SHIMS): a prospective national cohort study. 508 Lancet HIV. 2017 Feb 1;4(2): e83–92. 509 SHIMS2. Swaziland Hiv Incidence Measurement Survey 2: a Population-25. 510 Based Hiv Impact Assessment. 2017;(July 2017):1–4. Available from: 511 http://phia.icap.columbia.edu/wp-512 content/uploads/2017/11/Swaziland new.v8.pdf 513 26. PEPFAR. Eswatini surpasses UNAIDS Fast-track Targets for treatment and 514
 - viral suppression United States Department of State [Internet]. 2022 [cited

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

2022 Oct 14]. Available from: https://www.state.gov/eswatini-surpassesunaids-fast-track-targets-for-treatment-and-viral-suppression/ 27. Eswatini Meets Global 95-95-95 HIV Target - Blog - The Global Fund to Fight AIDS, Tuberculosis and Malaria [Internet]. [cited 2022 Oct 14]. Available from: https://www.theglobalfund.org/en/blog/2020-09-14-eswatini-meets-global-95-95-95-hiv-target/ 28. Nsibandze BS, Downing C, Poggenpoel M, Myburgh CPH. "I have been rejected so many times" experiences of female adolescents living with HIV in rural Manzini, Eswatini: A case study. Int J Afr Nurs Sci. 2021 Jan 1; 14:100307. Silvestre E. Measure Evaluation. 2017 [cited 2023 Aug 3]. p. 1 to 42 29. Implementing Swaziland's Client Management Information System: Stakeholder's Views of the Process and Recommendations to Improve it. Available from: https://www.measureevaluation.org/resources/publications/tr-17-226.html 30. Jobanputra K, Parker LA, Azih C, Okello V, Maphalala G, Kershberger B, et al. Factors associated with virological failure and suppression after enhanced adherence counselling, in children, adolescents and adults on antiretroviral therapy for HIV in Swaziland. PLoS One [Internet]. 2015;10(2): e0116144. Available from: http://dx.doi.org/10.1371/journal.pone.0116144 Ness TE, Agrawal V, Guffey D, Small A, Simelane T, Dlamini S, et al. Impact 31. of using creative arts programming to support HIV treatment in adolescents and young adults in Eswatini. AIDS Res Ther [Internet]. 2021 Dec 1 [cited

2022 Oct 23];18(1):1–7. Available from: 539 https://aidsrestherapy.biomedcentral.com/articles/10.1186/s12981-021-00423-540 2 541 32. Ministry of Health. Kingdom of Eswatini. Guidelines for Differentiated Service 542 Delivery [Internet]. Mbabane; 2022 [cited 2022 Nov 13]. Available from: 543 https://cquin.icap.columbia.edu/wp-content/uploads/2022/07/Final Policy-544 Guidelines-for-Eswatini-Differentiated-Service-Delivery.pdf 545 Dlamini-Simelane T, Mover E. Task shifting or shifting care practices? the 546 33. impact of task shifting on patients' experiences and health care arrangements 547 in Swaziland. BMC Health Serv Res. 2017 Jan 10;17(1). 548 Ahmed C V., Weissinger G, Teitelman A, Sabelo Dlamini N, Patience Dlamini 34. 549 N. Cebsile Dlamini T. et al. Expert client service delivery practices among 550 adolescents living with HIV in Eswatini: A thematic analysis. Child Youth Serv 551 Rev. 2022 Jan 1; 132:106309. 552 Ministry of Health. Swaziland. Swaziland Integrated HIV Management 553 35. Guidelines [Internet]. 2018 [cited 2022 Nov 15]. Available from: 554 http://swaziaidsprogram.org/wp-content/uploads/2021/07/2018-Integrated-HIV-555 Management-Guidelines final-1.pdf 556 36. Government of the Kingdom of Eswatini. Service Availability and Readiness 557 Assessment (SARA), 2017 [Internet]. Ministry of Health,: Mbabane. Mbabane; 558 2017 [cited 2022 Oct 25]. Available from: 559 https://www.hst.org.za/publications/NonHST%20Publications/Eswatini%20SA 560 RA%20March%20(05%2004%202019).pdf 561

37. Ministry Of Health Kingdom of Swaziland. 2018-Integrated-HIV-Management-562 Guidelines final-1.pdf [Internet]. Mbabane; 2018 [cited 2022 Nov 13]. Available 563 from: http://swaziaidsprogram.org/wp-content/uploads/2021/07/2018-564 Integrated-HIV-Management-Guidelines final-1.pdf 565 Sithole Z, Mbizvo E, Chonzi P, Mungati M, Juru TP, Shambira G, et al. 38. 566 Virological failure among adolescents on ART, Harare City, 2017- a case-567 control study. BMC Infect Dis. 2018;18(1):1-8. 568 Natukunda J, Kirabira P, Ong KIC, Shibanuma A, Jimba M. Virologic failure in 569 39. HIV-positive adolescents with perfect adherence in Uganda: a cross-sectional 570 study. Trop Med Health. 2019;47(1):1-10. 571 Meloni ST, Agaba P, Chang CA, Yiltok E, Oguche S, Ejeliogu E, et al. 40. 572 Longitudinal evaluation of adherence, retention, and transition patterns of 573 adolescents living with HIV in Nigeria. PLoS One. 2020;15(7): e0236801. 574 41. Cluver LD, Toska E, Orkin FM, Meinck F, Hodes R, Yakubovich AR, et al. 575 Achieving equity in HIV-treatment outcomes: can social protection improve 576 adolescent ART-adherence in South Africa? AIDS Care [Internet]. 577 2016;28(sup2):73–82. Available from: 578 http://dx.doi.org/10.1080/09540121.2016.1179008 579 580 42. Zhou S, Cluver L, Shenderovich Y, Toska E. Uncovering ART adherence inconsistencies: An assessment of sustained adherence among adolescents in 581 South Africa. J Int AIDS Soc [Internet]. 2021 Oct 1 [cited 2023 Mar 4];24(10). 582 Available from: /pmc/articles/PMC8552454/ 583

43. Cluver L, Meinck F, Toska E, Orkin FM, Hodes R, Sherr L. Multitype violence 584

- exposures and adolescent antiretroviral nonadherence in South Africa. AIDS. 585
- 586 2018;32(8):975.
- 44. Gray KL, Kiazolu M, Jones J, Konstantinova A, Zawolo JSW, Gray WMH, et al. 587
- Liberia adherence and loss-to-follow-up in HIV and AIDS care and treatment: 588
- A retrospective cohort of adolescents and adults from 2016–2019. PLOS 589
- Global Public Health. 2022;2(3). 590
- Kerschberger B, Schomaker M, Jobanputra K, Kabore SM, Teck R, Mabhena 591 45.
- E, et al. HIV programmatic outcomes following implementation of the "Treat-592
- All" policy in a public sector setting in Eswatini: a prospective cohort study. J 593
- Int AIDS Soc [Internet]. 2020 Mar 1 [cited 2023 Feb 8];23(3). Available from: 594
- https://pubmed.ncbi.nlm.nih.gov/32128964/ 595
- Horter S, Thabede Z, Dlamini V, Bernays S, Stringer B, Mazibuko S, et al. "Life 46. 596
- is so easy on ART, once you accept it": Acceptance, denial and linkage to HIV 597
- care in Shiselweni, Swaziland. Soc Sci Med. 2017 Mar 1; 176:52-9. 598
- 47. Barbara Sibbald. Responding to Swaziland's dual epidemic. CMAJ [Internet]. 599
- 2013 Jan 1 [cited 2023 Feb 8];185(1): E13-4. Available from: 600
- https://www.cmaj.ca/content/cmaj/185/1/E13.full.pdf 601
- 602 48. PEPFAR. Eswatini Country Operational Plan (COP/ROP) 2020 Strategic
- Direction Summary. 2020. 603
- 49. Nabukeera-Barungi N, Elyanu P, Asire B, Katureebe C, Lukabwe I, Namusoke 604
- E, et al. Adherence to antiretroviral therapy and retention in care for 605

adolescents living with HIV from 10 districts in Uganda. BMC Infect Dis. 606 2015;15(1):1-10. 607 50. Thirumurthy H, Ndyabakira A, Marson K, Emperador D, Kamya M, Havlir D, et 608 al. Financial incentives for achieving and maintaining viral suppression among 609 HIV-positive adults in Uganda: a randomised controlled trial. Lancet HIV. 2019 610 Mar;6(3): e155-63. 611 51. Fahey CA, Njau PF, Katabaro E, Mfaume RS, Ulenga N, Mwenda N, et al. 612 Financial incentives to promote retention in care and viral suppression in 613 adults with HIV initiating antiretroviral therapy in Tanzania: a three-arm 614 randomised controlled trial. Lancet HIV. 2020 Nov;7(11): e762–71. 615 Bermudez LG, Jennings L, Ssewamala FM, Nabunya P, Mellins C, McKay M. 52. 616 Equity in adherence to antiretroviral therapy among economically vulnerable 617 adolescents living with HIV in Uganda. AIDS Care - Psychological and Socio-618 Medical Aspects of AIDS/HIV [Internet]. 2016;28(sup2):83–91. Available from: 619 https://doi.org/10.1080/09540121.2016.1176681 620 53. Linnemayr S, Stecher C, Mukasa B. Behavioral economic incentives to 621 improve adherence to antiretroviral medication. Aids. 2017;31(5):719–26. 622 Bezabih T, Weiser SD, Menbere MS, Negash A, Grede N. Comparison of 54. 623 treatment adherence outcome among PLHIV enrolled in economic 624 strengthening program with community control. AIDS Care. 2018 625 Mar;30(3):369–77. 626 55. Cluver LD, Hodes RJ, Toska E, Kidia KK, Orkin FM, Sherr L, et al. "HIV is like 627 a tsotsi. ARVs are your guns": Associations between HIV-disclosure and 628

adherence to antiretroviral treatment among adolescents in South Africa. Aids. 629 2015;29(April): S57-65. 630 Ramos J V, Mmbaga BT, Turner EL, Rugalabamu LL, Luhanga S, 56. 631 Cunningham CK, et al. Modality of Primary HIV Disclosure and Association 632 with Mental Health, Stigma, and Antiretroviral Therapy Adherence in 633 Tanzanian Youth Living with HIV. AIDS Patient Care STDS. 2018 634 Jan;32(1):31–7. 635 Stangl AL, Mwale M, Sebany M, Mackworth-Young CRS, Chiiya C, Chonta M, 636 57. et al. Feasibility, Acceptability and Preliminary Efficacy of Tikambisane ('Let's 637 Talk to Each Other'): A Pilot Support Group Intervention for Adolescent Girls 638 Living with HIV in Zambia. J Int Assoc Provid AIDS Care. 2021;20. 639 640 58. Merzel C, VanDevanter N, Irvine M. Adherence to antiretroviral therapy among older children and adolescents with HIV: A qualitative study of psychosocial 641 contexts. AIDS Patient Care STDS. 2008;22(12). 642 Ankrah DNA, Koster ES, Mantel-Teeuwisse AK, Arhinful DK, Agyepong IA, 643 59. Lartey M. Facilitators and barriers to antiretroviral therapy adherence among 644 adolescents in Ghana. Patient Prefer Adherence. 2016; 10:329-37. 645 Xu L. Munir K. Kanabkaew C. Le Coeur S. Factors influencing antiretroviral 60. 646 treatment suboptimal adherence among perinatally HIV infected adolescents in 647 Thailand. PLoS One. 2017;12(2):1-18. 648 61. Bvochora T, Satyanarayana S, Takarinda KC, Bara H, Chonzi P, Komtenza B, 649 et al. Enhanced adherence counselling and viral load suppression in HIV 650 seropositive patients with an initial high viral load in Harare, Zimbabwe: 651

Operational issues. PLoS One [Internet]. 2019 Feb 1 [cited 2023 Jan 24];14(2): 652 e0211326. Available from: 653 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211326 654 62. Hussen S, Mama M, Mekonnen B, Yihune M, Shegaze M, Boti N, et al. 655 Predictors of Time to Viral Load Suppression of Adult PLWHIV on ART in Arba 656 Minch General Hospital: A Follow up Study. Ethiop J Health Sci [Internet]. 657 2019 Nov 19 [cited 2023 Jan 24];29(6):751–8. Available from: 658 https://www.ajol.info/index.php/ejhs/article/view/191325 659 Diress G, Dagne S, Alemnew B, Adane S, Addisu A. Viral Load Suppression 63. 660 after Enhanced Adherence Counseling and Its Predictors among High Viral 661 Load HIV Seropositive People in North Wollo Zone Public Hospitals, Northeast 662 Ethiopia, 2019: Retrospective Cohort Study. AIDS Res Treat. 2020;2020. 663 Ross-Degnan D, Pierre-Jacques M, Zhang F, Tadeg H, Gitau L, Ntaganira J, 64. 664 et al. Measuring adherence to antiretroviral treatment in resource-poor 665 settings: The clinical validity of key indicators. BMC Health Serv Res. 2010; 666 10:42. 667 Chalker JC, Andualem T, Gitau LN, Ntaganira J, Obua C, Tadeg H, et al. 65. 668 Measuring adherence to antiretroviral treatment in resource-poor settings: The 669 feasibility of collecting routine data for key indicators. BMC Health Serv Res 670 [Internet]. 2010 Feb 19 [cited 2022 Oct 27];10(1):1–11. Available from: 671 672 https://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-10-43 Gebreeyesus F, Mitku D, Tarekegn T, Temere B, Terefe T, Belete A, et al. 66. 673 Levels of Adherence and Associated Factors Among Children on ART Over 674

Time in Northwest, Ethiopia: Evidence from a Multicenter Follow-Up Study. 675 2021 [cited 2022 Oct 25]; Available from: https://doi.org/10.2147/HIV.S323090 676 Ba J, Id V, Katsabola H, Bvumbwe Id M, Mhango J, Silverstein Id A, et al. 67. 677 Factors associated with antiretroviral therapy adherence among adolescents 678 living with HIV in the era of isoniazid preventive therapy as part of HIV care. 679 PLOS Global Public Health [Internet]. 2022 Jun 2 [cited 2022 Oct 18];2(6): 680 e0000418. Available from: 681 https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.000 682 0418 683 Kabogo J, Muniu E, Wamunyokoli F, Musoke R, Songok E. Evidence of 68. 684 reduced treatment adherence among HIV infected paediatric and adolescent 685 populations in Nairobi at the onset of the UNAIDS Universal Test and Treat 686 Program. BMC Res Notes. 2018;11(1):1-7. 687 Alhaj M. Amberbir A. Singogo E. Banda V. van Lettow M. Matengeni A. et al. 69. 688 Retention on antiretroviral therapy during Universal Test and Treat 689 implementation in Zomba district, Malawi: a retrospective cohort study. J Int 690 691 AIDS Soc. 2019;22(2). Havlir D, Lockman S, Ayles H, Larmarange J, Chamie G, Gaolathe T, et al. 70. 692 What do the Universal Test and Treat trials tell us about the path to HIV 693 epidemic control? Vol. 23, Journal of the International AIDS Society. 2020. 694 Herce ME, Hoffmann CJ, Fielding K, Topp SM, Hausler H, Chimoyi L, et al. 71. 695 Universal test-and-treat in Zambian and South African correctional facilities: a 696 multisite prospective cohort study. Lancet HIV. 2020;7(12). 697

698 72. Mugenyi L, Nanfuka M, Byawaka J, Agaba C, Mijumbi A, Kagimu D, et al. Effect of universal test and treat on retention and mortality among people living 699 with HIV-infection in Uganda: An interrupted time series analysis. PLoS One 700 [Internet]. 2022 May 1 [cited 2022 Oct 21];17(5): e0268226. Available from: 701 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0268226 702 73. Barlow-Mosha L. Musiime V. Davies MA, Prendergast AJ, Musoke P. Siberry 703 G, et al. Universal antiretroviral therapy for HIV-infected children: a review of 704 the benefits and risks to consider during implementation. J Int AIDS Soc. 2017 705 Jun;20(1):21552. 706